PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression.

Multi-drug resistance (MDR) represents a major obstacle for chemotherapeutic treatment of a wide variety of human cancers. Increased expression of drug efflux pumps, such as the P-glycoprotein (P-gp) have been linked to development of MDR. Herein, we have identified protein kinase D isoform 2 (PKD2) as an important regulator of MDR and P-gp expression in paclitaxel-treated breast cancer cell lines.